Baseline characteristics of HPS participants by prior diabetes HPS: Baseline lip

Baseline characteristics of HPS participants by prior diabetes HPS: Baseline lip www.phwiki.com

Baseline characteristics of HPS participants by prior diabetes HPS: Baseline lip

Moore, Deborah, Executive Editor and Publisher has reference to this Academic Journal, PHwiki organized this Journal Baseline characteristics of HPS participants by prior diabetes HPS: Baseline lipids (mmol/L) in addition to apolipoproteins (g/L) by prior diabetes HPS: Baseline lipids (mg/dL) in addition to apolipoproteins (g/L) by prior diabetes

Bugema University UG www.phwiki.com

This Particular University is Related to this Particular Journal

HPS: FACTORIAL TREATMENT COMPARISONS HPS: Mean (SE) differences in lipids during follow-up by diabetes

SIMVASTATIN: MAJOR VASCULAR EVENT by YEAR in DIABETIC PATIENTS SIMVASTATIN PLACEBO Rate ratio & 95% CI STATIN better PLACEBO better Year of follow-up (2978) (2985) 1 143 141 (4.8%) (4.7%) 2 110 150 (3.9%) (5.3%) 3 109 172 (4.0%) (6.5%) 4 101 138 (3.9%) (5.6%) 5+ 138 147 (5.7%) (6.4%) ALL FOLLOW-UP 601 748 (20.2%) (25.1%) 22% SE 5 reduction (2P<0.00001) 0.4 0.6 0.8 1.0 1.2 1.4 People suffering events (%) SIMVASTATIN: MAJOR VASCULAR EVENTS by DURATION OF DIABETES SIMVASTATIN PLACEBO Rate ratio & 95% CI STATIN better PLACEBO better Duration (years) (10269) (10267) <6 203 247 (18.9%) (23.0%) 6 <13 201 241 (20.8%) (25.6%) 13 197 259 (21.0%) (26.7%) No diabetes 1432 1837 (19.6%) (25.2%) ALL PATIENTS 2033 2585 (19.8%) (25.2%) 24% SE 3 reduction (2P<0.00001) 0.4 0.6 0.8 1.0 1.2 1.4 SIMVASTATIN: HbA1c (% ± SE) among a sample with DIABETES at entry SIMVASTATIN: Development of DIABETES in patients not known to have diabetes at entry SIMVASTATIN: Change in blood CREATININE (µmol/l ± se) from baseline to 4 years HPS: Effects of SIMVASTATIN on first in addition to all major vascular events in those with in addition to without diabetes Proportional Risk reductions (SE): Absolute/1000 P-value Absolute effects of simvastatin allocation on 5-year rates of first major vascular event 40 Proportion with first major vascular event (%) 32.9% (9.1) 44 (12) 0.0003 24.5% (3.1) 62 (8) <0.0001 18.4% (5.7) 66 (21) 0.002 S=simvastatin-allocated P=placebo-allocated Moore, Deborah School Planning & Management Executive Editor and Publisher www.phwiki.com

HPS: Conclusions as long as people with diabetes Lowering LDL cholesterol by 1 mmol/L (40 mg/dL) reduces the risk of major vascular events by about one-quarter during 5 years of treatment Similar proportional reductions in risk among people with or without diabetes irrespective of age, sex, vascular disease or lipid levels Continued statin treatment prevents not only first but also subsequent major vascular events

Moore, Deborah Executive Editor and Publisher

Moore, Deborah is from United States and they belong to School Planning & Management and they are from  Phoenix, United States got related to this Particular Journal. and Moore, Deborah deal with the subjects like Education

Journal Ratings by Bugema University

This Particular Journal got reviewed and rated by Bugema University and short form of this particular Institution is UG and gave this Journal an Excellent Rating.